Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › daclatasvir

daclatasvir

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of daclatasvir

26 trials tracked of daclatasvir: 12 in phase 3 or 4 and 1 with published results. The most-cited published study has 38 citations.

26Trials tracked
12Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 11 Phase 2 12 Phase 1 2
  1. Phase 3 A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection Completed · 38 cited
  2. Phase 4 Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics Completed
  3. Phase 3 Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection Completed
  4. Phase 3 Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis Completed
  5. Phase 3 Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia Completed
  6. Phase 3 Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual Completed
Show 20 more trials
  1. Phase 3 Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Completed
  2. Phase 3 Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV Completed
  3. Phase 3 Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant Completed
  4. Phase 3 Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus Completed
  5. Phase 3 BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C Completed
  6. Phase 3 A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. Completed
  7. Phase 2 Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus Completed
  8. Phase 2 Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection Completed
  9. Phase 2 Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials Completed
  10. Phase 2 Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin) Completed
  11. Phase 2 A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects Completed
  12. Phase 2 Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients Completed
  13. Phase 2 Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin) Completed
  14. Phase 2 An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease Completed
  15. Phase 2 A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation Completed
  16. Phase 2 A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants Completed
  17. Phase 2 A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects Completed
  18. Phase 2 Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care Completed
  19. Phase 1 Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment Completed
  20. Phase 1 Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants Completed

Showing the 26 most-cited and recently-updated of 26 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Machine learning models predict SVR in comorbid HCV patients treated with sofosbuvir, daclatasvir, and ribavirin in Pakistan
Primary Care & Family Medicine Cohort
Machine learning models predict SVR in comorbid HCV patients treated with sofosbuvir, daclatasvir, and ribavirin in Pakistan Can a computer predict your hepatitis C cure?
This retrospective cohort study evaluated machine learning prediction models in 221 comorbid HCV patients in Pakistan.
A new computer tool can spot which hepatitis C patients are likely to fail treatment before they even start taking pills.
Frontiers Apr 13, 2026